Occupational Therapists in Firestone, CO Accepting Medicare

8 Occupational Therapists found. Showing 1 - 8

Mrs. Stacey Michelle Schulte, OTR Occupational Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 6937 Tenderfoot Ave, Firestone, CO 80504 Phone: 720-890-7222

Emily Rae Bilek, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 10184 E I25 Frontage Rd, Firestone, CO 80504 Phone: 720-378-6670

Mr. Garrett Matthew Breitbarth, OTR Occupational Therapist - Pediatrics Medicare: Medicare Enrolled Practice Location: 11169 E I25 Frontage Rd, Firestone, CO 80504 Phone: 720-378-6670

Leah Cohen, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 10184 E I25 Frontage Rd, Firestone, CO 80504 Phone: 720-378-6670

Danielle Christen Geyer, MOT, OTR/L Occupational Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 11169 E I25 Frontage Rd, Suite B, Firestone, CO 80504 Phone: 720-378-6670

Elizabeth Large, M.S., OTR/L Occupational Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 10184 E I25 Frontage Rd, Firestone, CO 80504 Phone: 720-378-6670

Kathryn Prussin Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 10290 Neighbors Pkwy, Firestone, CO 80504 Phone: 720-652-8240

Kelsey Bonavida Occupational Therapist Medicare: Medicare Enrolled Practice Location: 11169 E I25 Frontage Rd, Firestone, CO 80504 Phone: 720-378-6670

News Archive

Montreal Heart Institute and Cerenis commence CER-001 Phase 2 study in acute coronary syndrome

The Montreal Heart Institute today announced the start of the Phase 2 CHI-SQUARE (Can HDL Infusions Significantly QUicken Atherosclerosis REgression?) study of CER-001 in patients with acute coronary syndrome (ACS), in collaboration with Cerenis Therapeutics, a biopharmaceutical company developing novel high-density lipoprotein (HDL) therapies to treat cardiovascular and metabolic diseases.

Study: Novavax Covid-19 vaccine is efficacious against the B.1.351 South African variant

The published data provide additional detail of an initial analysis conducted in January, while more robust data from a complete analysis of the study was subsequently shared in March 2021.

Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S today announced that the companies will be presenting new data from four studies that evaluated effectiveness in treating the overall symptoms of depression in patients taking vortioxetine, an investigational agent under review with the U.S. Food and Drug Administration for the treatment of major depressive disorder.

Greatbatch acquires NeuroNexus

Greatbatch, Inc., today announced the acquisition of NeuroNexus Technologies for approximately $12 million in cash, including the assumption of debt and future considerations.

NewLink Genetics reports positive data from Phase 2 trial of HyperAcute-Pancreas cancer immunotherapy

NewLink Genetics Corporation today announced positive Phase 2 clinical trial data of its HyperAcute®-Pancreas cancer immunotherapy combined with standard adjuvant chemotherapy in patients with surgically resectable pancreatic cancer. The study results suggest a potentially longer disease-free survival and one-year overall survival in this patient group than reported in previous studies of surgery and adjuvant therapy alone. These data were presented in a poster session at the American Society of Clinical Oncology (ASCO) annual meeting.

Read more Medical News

› Verified 6 days ago